<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362301">
  <stage>Registered</stage>
  <submitdate>26/03/2012</submitdate>
  <approvaldate>27/03/2012</approvaldate>
  <actrnumber>ACTRN12612000352808</actrnumber>
  <trial_identification>
    <studytitle>Investigation of whether metformin can be used safely and effectively in patients with type 2 diabetes on haemodialysis</studytitle>
    <scientifictitle>A short term study of safety and glycaemic outcomes in haemodialysis patients with type 2 diabetes treated with metformin</scientifictitle>
    <utrn>U1111-1129-4788</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 Diabetes</healthcondition>
    <healthcondition>Chronic Renal failure on haemodialysis</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Metformin dosed orally at 500mg within one hour post each haemodialysis session for 3 weeks (after 9 dialysis sessions)</interventions>
    <comparator>Own controls- assessed off drug initially</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Establishing a safe dosing regimen for metformin in patients on haemodialysis based on pharmacokinetic data collected after metformin is dosed.</outcome>
      <timepoint>Dialysis cycles 1,2, 3: Metformin concentrations and bicarbonate, lactate and pH measured at 120 min, 240min post metformin dose and the next morning, then prior to and post dialysis.
Dialysis cycles 4,5, 6,7,8: Metformin concentrations pre and post dialysis. Lactate, pH and Bicarbonate concentrations pre dialysis on cycle 6.
Dialysis cycle 9: Metformin concentrations pre dialysis and post dialysis at 120 min, 240min post metformin dose and the next morning, along with measurement of  bicarbonate, lactate and pH.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To describe the effects of metformin on diabetes control in patients with type 2 diabetes treated with haemodialysis -Metformin effect will be assessed by change in insulin sensitivity by the Homeostasis Model Assessment (HOMA2) and by change in average blood glucose measured by continutous glucose monitoring (CGMS).</outcome>
      <timepoint>Baseline and at 4 weeks for a 72 hour period each time</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>&gt; 18 years
Type 2 Diabetes
Receiving haemodialysis 3 times a week for greater than 3 months
Patients in which metformin would normally be used if they had normal renal function.
Consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>100</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>(1)Any patients in whom metformin would not be used in the setting of normal renal function including: Moderate to severe heart failure, liver failure, alcohol abuse, major psychiatric disorder, acutely unwell or otherwise medically unstable.
(2)Unable or unwilling to self monitor and record blood glucose levels via glucometer readings.
(3)Inability to provide written informed consent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Allocation is not concealed</concealment>
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics / pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/04/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>6</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Tilenka Thynne</primarysponsorname>
    <primarysponsoraddress>Flinders Dr, 
Bedford Park 
SA 5042</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Department Clinical Pharmacology ,Flinders Medical Centre</fundingname>
      <fundingaddress>Flinders Dr, 
Bedford Park 
SA 5042</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Matthew Doogue</sponsorname>
      <sponsoraddress>Flinders Dr, 
Bedford Park 
SA 5042</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a study aiming to evaluate whether metformin, an antidiabetic medication, can be used safety and effectively in patients with type 2 diabetes who are receiving haemodialysis for their end stage kidney disease. The study runs over 4 weeks and 500mg of metformin (one tablet) will be given to participants after each dialysis session in weeks 2-4 of the study (9 times). 
We hypothesise that metformin can be safely used in patients with type 2 diabetes with end stage renal failure if dosed based on predicted drug clearance.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Adelaide Clinical Human Research Ethics Committee (SAC HREC)</ethicname>
      <ethicaddress>Flinders Dr, 
Bedford Park 
SA 5042</ethicaddress>
      <ethicapprovaldate>4/04/2012</ethicapprovaldate>
      <hrec>EC00188
Application Number: 324.11</hrec>
      <ethicsubmitdate>26/03/2012</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Matthew Doogue</name>
      <address>Department of Clinical Pharmacology
Flinders Medical Centre
Flinders Dr, 
Bedford Park 
SA 5042</address>
      <phone>+61 8 82045511</phone>
      <fax />
      <email>matt.doogue@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Tilenka Thynne</name>
      <address>Department of Clinical Pharmacology
Flinders Medical Centre
Flinders Dr, 
Bedford Park 
SA 5042</address>
      <phone>+61 8 82045511</phone>
      <fax />
      <email>tilenka.thynne@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Tilenka Thynne</name>
      <address>Department of Clinical Pharmacology
Flinders Medical Centre
Flinders Dr, 
Bedford Park 
SA 5042</address>
      <phone>+61 8 82045511</phone>
      <fax />
      <email>tilenka.thynne@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>